Drug Eluting Balloon Market (Product - Coronary Drug Eluting Balloon, Peripheral Drug Eluting Balloon; Drug Coating Technology - Paccocath, FreePac, TransPax, EnduraCoat)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

According to Nova one advisor, the global Drug Eluting Balloon market size is expected to hit around USD 5.9 billion by 2030 from valued at USD 1.3 billion in 2021 and growing at a CAGR of 16.04% from 2022 to 2030.

Drug-eluting balloons refer to semi-compliant angioplasty balloons that are coated with anti-proliferative medications and are dispersed in the walls of blood arteries following balloon inflation, which is typically done at minimal pressures. These balloons greatly reduce cellularity and remove the need for repeated vascularization. The increasing vascular disease rates, increased product advancements, and rising elderly population are all contributing to increasing demand for the drug-eluting balloon in the healthcare industry. However, the global drug eluting balloon market is predicted to develop slowly owing to the high cost of processes and goods, as well as tight regulatory rules.

Report Scope of the Drug Eluting Balloon Market

Key Trends and Analysis of the Global Drug Eluting Balloon Market:

Major players operating in the market are focusing on getting approval for new products and launching new products in the market. For instance, in February 2021, according to the U.S. Food and Drug Administration (FDA) continues to acknowledge a possible mortality risk with paclitaxel-coated balloons and stents intended to treat new or recurring atherosclerotic lesions in the femoropopliteal artery. A study of paclitaxel-coated stents and balloons used to treat peripheral artery disease in the legs found no evidence of harm associated with the devices, appearing to contradict an earlier mortality signal from a meta-analysis that FDA recommended physicians factor into treatment decisions. The U.S. Food and Drug Administration (FDA) still monitoring safety signal with paclitaxel stents in PAD. The researchers noted several limitations to the new study, including a shorter follow-up time of 2.72 years than the meta-analysis, in which the mortality signal was most apparent in the fourth and fifth years. The findings were presented in February 2021, at the American College of Cardiology’s virtual meeting and published in JAMA Internal Medicine. The SAFE-PAD researchers said the study is ongoing and will continue the safety evaluation of the devices until the median follow-up of all patients surpasses five years

Increasing Initiatives from Government and Private Players to Drives Sales Opportunities in the Market

Over the last decade, the healthcare infrastructure has seen significant changes as technology has advanced and healthcare research has exploded. Some of the causes driving demand for drug eluting balloon catheters are increasing incidences of obesity, an aging population, and a rise in occurrence of coronary artery disease. Stents that are utilized with a balloon catheter are referred to as balloon expandable stents, as opposed to self-expandable stents, which are often composed of nitinol alloy.

The global drug eluting balloon market is also benefiting from the increasing adoption of angioplasty balloons for patients who do not gain from percutaneous coronary intervention (PCI). Governments and other organizations are increasingly supporting research and providing financing to further develop drug eluting balloon catheters.

Drug eluting devices are used to lessen the incidence of restenosis and are most commonly connected with cardiac problems. Over the next 10 years, the market for peripheral drug-coated balloon catheters is expected to expand at a stable growth rate. As the benefits of drug-eluting balloon catheters are discovered and treatments become more inexpensive, the use of these catheters for peripheral artery operations is expected to rise.

Demand for coronary artery disease drug eluting balloon catheters is expected to account for over 80% of market share when it comes to value in the indication segment. Despite a small market share, the demand for drug-eluting balloon catheters for peripheral vascular disease is expected to grow at a stable CAGR in the years to come. With additional angioplasty balloons being studied and manufactured, sales of peripheral drug-coated balloon catheters are expected to rise as well.

Cardiovascular illnesses are a serious public-health concern. Peripheral artery disease (PAD) is a prevalent kind of peripheral vascular disease that affects persons over the age of 65 years. PAD causes the walls of arteries to thin, slowing blood flow. Although it most usually affects the peripheral areas, it can also damage the arteries that bring blood from the head to the heart, kidneys, and stomach. Given the rising prevalence of cardiovascular illnesses, it's critical to comprehend the elements that influence the extent of the diseases and the effective treatment choices available. A number of governmental and private players are making serious efforts through various initiatives in reducing the prevalence of cardiovascular disease. Governments  as well as physicians and in industrialized nations have begun to inform the common people about PAD.

Every September, medical device firms, doctors, payers, and health care providers in the U.S. commemorate 'PAD Awareness Month.' During the awareness initiative, they strive to inform people about the ill effects of PAD and how to manage it. Several government agencies are funding research groups to help them produce drug-eluting balloons that are more successful in treating cardiovascular disorders. In the forthcoming years, this is anticipated to boost the global drug eluting balloon market.

North America and Asia Pacific to Lead the Market due to High Prevalence of Cardiovascular Illnesses

North America region is expected to account for a prominent share in the global drug eluting balloon market. High rate of treatment as well as diagnosis of cardiovascular illnesses and increasing spending on healthcare is anticipated to augur well for the drug eluting balloon market in North America. Besides, greater penetration of innovative products along with favorable reimbursement policies is expected to drive sales growth in the regional market.

However, the expiration of TPT reimbursement on medication eluting balloons in December 2017 and ' tight regulatory system in the U.S. are expected to limit the drug eluting balloon market's growth in North America over the next two to three years. Due to the growing senior population, need for higher quality of care, and rise in the prevalence of cardiovascular illnesses in the area, the drug eluting balloon market in Asia Pacific is expected to provide substantial potential throughout the projected period.

Some of the prominent players in the Drug Eluting Balloon Market include:

• Medtronic plc
• Becton, Dickinson and Company
• Boston Scientific Corporation
• Cook Medical
• B. Braun Melsungen AG
• Koninklijke Philips N.V.
• Opto Circuits Limited
• Terumo Corporation
• Biotronik SE & Co. KG
• Innvolution Healthcare Pvt. Ltd

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Drug Eluting Balloon market

Product

• Coronary Drug Eluting Balloon
• Peripheral Drug Eluting Balloon
• Others

Technology

• Paccocath
• FreePac
• TransPax
• EnduraCoat
• Others

End-user

• Hospitals and Ambulatory Surgery Centers
• CATH Labs
• Others

By Geography

North America

• U.S.
• Canada

Europe

• Germany
• France
• United Kingdom
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Southeast Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Rest of Latin America

Middle East & Africa (MEA)

• GCC
• North Africa
• South Africa
• Rest of Middle East & Africa

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Drug Eluting Balloon industry analysis from 2022 to 2030 to identify the prevailing Drug Eluting Balloon industry opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the global Drug Eluting Balloon industry segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes te analysis of the regional as well as global Drug Eluting Balloon industry trends, key players, market segments, application areas, and market growth strategies.